Anthera Pharmaceuticals, Inc. (ANTH)
Anthera Pharmaceuticals, Inc.
The Pennzoil Building
Suite 1300 North Tower 700 Milam
Houston, TX 77002
United States
410 350 1839
https://www.anthera.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 21
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Paul F. Truex M.B.A. | Executive Chairman | 100k | N/A | 1969 |
| Mr. John Craig Thompson | CEO & Director | 715.3k | N/A | 1967 |
| Ms. May Liu | Senior VP of Finance & Administration and Principal Accounting Officer | 373.44k | N/A | 1976 |
| Dr. Paul Adams Ph.D. | Senior Vice President of Global Regulatory Affairs and Compliance | N/A | N/A | 1963 |
| Joshua Caldwell | Chief Liquidating Officer | N/A | N/A | N/A |
Description
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Corporate governance
Anthera Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
